When was zotuximab launched? What are its marketing background and clinical applications?

Zolbetuximab (zolbetuximab) is a new type of monoclonal antibody drug, mainly used to treat gastric cancer, especially patients with HER2 negative and expressing Claudin-18.2 gastric adenocarcinoma. This drug was developed by ImmunoGen and has obtained positive results in multiple clinical trial phases. Zotuximab will be launched in 2023 and has shown significant efficacy in clinical trials, becoming a new treatment option, especially in patients with poor efficacy of immune checkpoint inhibitors.

The background of the marketing of zotuximab is that gastric cancer is a malignant tumor with high incidence and high mortality. Existing treatments, such as chemotherapy and immunotherapy, are often unable to effectively control the progression of advanced gastric cancer. Therefore, developing therapeutic drugs targeting specific targets has become an important direction in the current field of cancer treatment. Zotuximab targets the Claudin-18.2 protein, which is highly expressed on the surface of gastric cancer cells. It can selectively fight gastric cancer cells without affecting normal cells, thereby reducing side effects and improving efficacy.

The clinical application of zotuximab is mainly focused on the treatment of gastric cancer, especially in patients with HER2 negative and Claudin-18.2 high expression of gastric adenocarcinoma. Clinical studies have shown that the combination of zotuximab and chemotherapy drugs can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients. The approval of the drug provides a new treatment option for patients with drug-resistant gastric cancer, especially those who have failed traditional treatments, increasing treatment options.

Currently, zotuximab is not available in all countries and regions, but as clinical research advances, its approval and use are gradually expanding globally. Due to its strong targeting and fewer side effects, zotuximab is expected to play an increasingly important role in the treatment of gastric cancer in the future, bringing more hope to gastric cancer patients worldwide.

Reference materials:https://www.astellas.com/en/news/29401